BIONIK LABORATORIES CORP. (BNKL) financial statements (2021 and earlier)
Company profile
| Business Address |
483 BAY STREET TORONTO, ON M5G2C9 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| SIC | 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1 | 2 | 0 | 1 | 1 | 7 | 0 | ||
| Cash and cash equivalents | 1 | 2 | 0 | 1 | 1 | 7 | 0 | ||
| Receivables | 0 | 1 | 2 | 0 | 0 | 0 | |||
| Inventory, net of allowances, customer advances and progress billings | 1 | 1 | 0 | 0 | 0 | ||||
| Inventory | 1 | 1 | 0 | 0 | 0 | ||||
| Prepaid expense | 2 | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed current assets | 2 | 1 | 0 | 0 | 0 | ||||
| Total current assets: | 4 | 6 | 4 | 1 | 1 | 7 | 0 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Intangible assets, net (including goodwill) | 5 | 13 | 27 | 27 | 27 | ||||
| Goodwill | 4 | 11 | 22 | 22 | 22 | ||||
| Intangible assets, net (excluding goodwill) | 1 | 1 | 4 | 5 | 5 | ||||
| Total noncurrent assets: | 5 | 13 | 27 | 27 | 28 | 0 | |||
| TOTAL ASSETS: | 9 | 19 | 31 | 29 | 29 | 7 | 0 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 3 | 3 | 3 | 2 | 2 | 0 | 0 | ||
| Accounts payable | 1 | 1 | 1 | 1 | 1 | 0 | |||
| Accrued liabilities | 2 | 2 | 2 | 2 | 1 | 0 | |||
| Other undisclosed accounts payable and accrued liabilities | 0 | ||||||||
| Deferred revenue | 0 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 4 | 2 | 0 | 1 | |||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | ||||
| Customer advances and deposits | ✕ | ✕ | ✕ | 0 | 0 | ||||
| Other undisclosed current liabilities | 0 | 0 | 6 | 3 | 0 | ||||
| Total current liabilities: | 7 | 5 | 3 | 8 | 6 | 0 | 0 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 0 | ||||||||
| Deferred revenue | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Total noncurrent liabilities: | 0 | ||||||||
| Other undisclosed liabilities | 6 | ||||||||
| Total liabilities: | 8 | 5 | 3 | 8 | 6 | 6 | 0 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 1 | 13 | 27 | 20 | 23 | 1 | (0) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Additional paid in capital | 85 | 85 | 74 | 56 | 39 | 11 | (0) | ||
| Accumulated other comprehensive income | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Accumulated deficit | (84) | (71) | (46) | (36) | (16) | (11) | (0) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | |||||||
| Total stockholders' equity: | 1 | 13 | 27 | 20 | 23 | 1 | (0) | ||
| TOTAL LIABILITIES AND EQUITY: | 9 | 19 | 31 | 29 | 29 | 7 | 0 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
| Revenue, net | ✕ | ✕ | ✕ | 1 | 1 | |||
| Other operating income | 0 | 0 | 0 | 0 | ||||
| Cost of revenue | (0) | (1) | (2) | (0) | (0) | (0) | ||
| Cost of goods and services sold | (0) | (1) | (2) | (0) | (0) | |||
| Other undisclosed gross profit | 1 | 2 | 3 | |||||
| Gross profit: | 1 | 1 | 2 | 1 | 0 | 0 | (0) | |
| Operating expenses | (16) | (12) | (11) | (10) | (9) | (6) | (0) | |
| Operating loss: | (15) | (11) | (9) | (10) | (9) | (6) | (0) | |
| Nonoperating income (expense) | (14) | (14) | (1) | (5) | 9 | 1 | ||
| Investment income, nonoperating | 4 | 0 | ||||||
| Other nonoperating income (expense) | (14) | (14) | (1) | (5) | 5 | 0 | ||
| Interest and debt expense | (0) | 0 | (1) | (0) | (0) | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (0) | 1 | (4) | (1) | ||||
| Loss before gain (loss) on sale of properties: | (29) | (25) | (11) | (15) | (4) | (6) | (0) | |
| Other undisclosed net income | 37 | 50 | ||||||
| Net income (loss): | 8 | 25 | (11) | (15) | (4) | (6) | (0) | |
| Other undisclosed net income attributable to parent | 13 | 21 | ||||||
| Net income (loss) available to common stockholders, diluted: | 21 | 25 | 11 | (15) | (4) | (6) | (0) | |
Comprehensive Income ($ in millions)
| 12/31/2020 TTM | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 8 | 25 | (11) | (15) | (4) | (6) | (0) | |
| Comprehensive income (loss): | 8 | 25 | (11) | (15) | (4) | (6) | (0) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (37) | (50) | 0 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (29) | (25) | (11) | (15) | (4) | (6) | (0) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.